Fiera Capital Corp Has $8.70 Million Stake in PROCEPT BioRobotics Corporation $PRCT

Fiera Capital Corp grew its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 29.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 276,494 shares of the company’s stock after purchasing an additional 63,192 shares during the period. Fiera Capital Corp’s holdings in PROCEPT BioRobotics were worth $8,699,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRCT. Center for Financial Planning Inc. purchased a new stake in PROCEPT BioRobotics in the 4th quarter worth approximately $40,000. US Bancorp DE grew its stake in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after buying an additional 1,079 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in PROCEPT BioRobotics by 90.7% in the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock worth $98,000 after purchasing an additional 810 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after purchasing an additional 337 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in PROCEPT BioRobotics by 24.0% in the 3rd quarter. IFP Advisors Inc now owns 5,024 shares of the company’s stock worth $179,000 after purchasing an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Wall Street Analyst Weigh In

PRCT has been the subject of several analyst reports. Robert W. Baird assumed coverage on PROCEPT BioRobotics in a report on Friday, March 6th. They issued a “neutral” rating and a $30.00 target price for the company. Oppenheimer restated a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Bank of America cut PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $38.00 to $20.00 in a research report on Thursday, February 26th. Piper Sandler reiterated an “overweight” rating and issued a $35.00 price target (up from $28.00) on shares of PROCEPT BioRobotics in a research report on Thursday, April 30th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $41.45.

PROCEPT BioRobotics Trading Up 1.9%

NASDAQ PRCT opened at $28.35 on Tuesday. The stock’s 50-day moving average is $25.66 and its 200-day moving average is $28.38. PROCEPT BioRobotics Corporation has a one year low of $19.35 and a one year high of $64.92. The firm has a market cap of $1.61 billion, a P/E ratio of -15.58 and a beta of 0.85. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). The firm had revenue of $83.13 million during the quarter, compared to analyst estimates of $80.52 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.45) EPS. Sell-side analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 5,363 shares of PROCEPT BioRobotics stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $25.96, for a total transaction of $139,223.48. Following the completion of the transaction, the executive vice president directly owned 105,354 shares in the company, valued at approximately $2,734,989.84. The trade was a 4.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 6,373 shares of company stock worth $167,655. Insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.